Dabigatran as anticoagulant therapy for atrial fibrillation. Which patients should receive it, which patients may not need it, and other practical aspects of patient management

Polskie Archiwum Medycyny Wewnetrznej

Volumn 121, Issue 3, 2011, Pages 73-80

  Douketis, James D ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

New anticoagulants; Perioperative anticoagulation; Pharmacodynamics; Pharmacokinetics

Indexed keywords

AMIODARONE; ANTIVITAMIN K; APIXABAN; CLARITHROMYCIN; DABIGATRAN; FONDAPARINUX; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; QUINIDINE; RIFAMPICIN; RIVAROXABAN; VERAPAMIL; WARFARIN;

ANTICOAGULANT THERAPY; BLEEDING; BRAIN HEMORRHAGE; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG MECHANISM; DRUG SAFETY; ELECTIVE SURGERY; EMBOLISM; HALF LIFE TIME; HEART ATRIUM FIBRILLATION; HUMAN; INVASIVE PROCEDURE; PATIENT CARE; REVIEW; STROKE;

EID: 79954469124     PISSN: 00323772     EISSN: None     Source Type: Journal    
DOI: 10.20452/pamw.1027     Document Type: Review

References (34)

1. Eriksson BI, Quinlan DJ, Weitz JI. Comparative pharmacodynamics and pharmacokinetics of oral direct thrombin and factor Xa inhibitors in development. Clin Pharmacokinet. 2009; 48: 1-22.
2. Sobieraj-Teague M, O'Donnell M, Eikelboom J. New anticoagulants for atrial fibrillation. Semin Thromb Hemost. 2009; 35: 515-524.
3. Apostolakis S, Lip GY, Lane DA, Shantsila E. The quest for new anticoagulants: From clinical development to clinical practice. Cardiovasc Ther. 2010 Jun 14. [Epub ahead of print].
4. Samama MM, Gerotziafas GT. Newer anticoagulants in 2009. J Thromb Thrombolysis. 2010; 29: 92-104.
5. Karthikeyan G, Eikelboom JW, Hirsh J. Dabigatran: ready for prime time? Pol Arch Med Wewn. 2010; 120: 137-142.
6. Karthikeyan G, Eikelboom JW, Hirsh J. New oral anticoagulants: not quite there yet. Pol Arch Med Wewn. 2009; 119: 53-59.
7. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009; 361: 1139-1151.
8. ROCKET AF Study Investigators. Rivaroxaban-once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation: rationale and design of the ROCKET AF study. Am Heart J. 2010; 159: 340-347.e1.
9. Wallentin L, Yusuf S, Ezekowitz MD, et al. Efficacy and safety of dabigatran compared with warfarin at different levels if international normalized ratio control for the stroke prevention in atrial fibrillation: an analysis of the RE-LY trial. Lancet. 2010; 376: 975-983.
10. Schulman S, Kearon C, Kakkar AK, et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med. 2009; 361: 2342-2352.
11. Olsson SB; Executive Steering Committee of the SPORTIF III Investigators. Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomized controlled trial. Lancet. 2003; 362: 1691-1698.
12. Albers GW, Diener HC, Frison L, et al.; Sportif Executive Steering Committee for the SPORTIF V investigators. Ximelagatran vs warfarin for stroke prevention in patients with non-valvular atrial fibrillation. A randomized trial. JAMA. 2005; 293: 690-698.
13. Hauel NH, Nar H, Priepke H, et al. Structure-based design of novel potent nonpeptide thrombin inhibitors. J Med Chem. 2002; 45: 1757-1766.
14. Wienen W, Stassen JM, Priepke H, et al. In-vitro profile and ex-vivo anticoagulant activity of the direct thrombin inhibitor dabigatran and its orally active prodrug, dabigatran etexilate. Thromb Haemost. 2007; 98: 155-162.
15. Stangier J. Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate. Clin Pharmacokinet 2008; 47: 285-295.
16. Stangier J, Rathgen K, Stahle H, et al. The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. Br J Clin Pharmacol. 2007; 64: 292-303.
17. Stangier J, Stähle H, Rathgen K, Fuhr R. Pharmokinetics and pharmacodynamics of the direct oral thrombin inhibitor dabigatran in healthy elderly subjects. Clin Pharmacokinet. 2008; 47: 47-59.
18. Sørensen R, Hansen ML, Abildstrom SZ, et al. Risk of bleeding in patients with acute myocardial infarction treated with different combinations of aspirin, clopidogrel, and vitamin K antagonists in Denmark: a retrospective analysis of nationwide registry data. Lancet. 2009; 374: 1967-1974.
19. Connolly SJ, Pogue J, Eikelboom J, et al.; ACTIVE W Investigators. Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range. Circulation. 2008; 118: 2029-2037.
20. Cromheecke ME, Levi M, Colly LP, et al. Oral anticoagulation self-management and management by a specialist anticoagulation clinic: a randomised cross-over comparison. Lancet. 2000; 356: 97-102.
21. Sawicki PT. A structured teaching and self-management program for patients receiving oral anticoagulation a randomized controlled trial. Working Group for the Study of Patient Self-Management of Oral Anticoagulation. JAMA. 1999; 281: 145-150.
22. Wilson SJ, Wells PS, Kovacs MJ, et al. Comparing the quality of oral anticoagulant management by anticoagulation clinics and by family physicians: a randomized controlled trial. CMAJ. 2003; 169: 293-298.
23. Douketis J, Arneklev K, Goldhaber SZ, et al. Comparison of bleeding in patients with nonvalvular atrial fibrillation treated with ximelagatran or warfarin: assessment of incidence, case-fatality rate, time course and sites of bleeding, and risk factors for bleeding. Arch Intern Med. 2006; 166: 853-859.
24. Gage BF, Waterman AD, Shannon W, et al. Validation of clinical classification schemes for predicting stroke: results from the national registry of atrial fibrillation. JAMA. 2001; 285: 2864-2870.
25. Lip GY, Nieuwlaat R, Pisters R, et al. Refining clinical risk stratification for predicting stroke in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey on atrial fibrillation. Chest. 2010; 137: 263-272.
26. Pisters R, Lane DA, Nieuwlaat R, et al. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in atrial fibrillation patients: the Euro Heart Survey. Chest. 2010; 138: 1093-1100.
27. European Heart Rhythm Association; European Association for Cardio-Thoracic Surgery. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J. 2010; 31: 2369-2429.
28. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976; 16: 31-41.
29. Crowther MA. Oral anticoagulant initiation: rationale for the use of warfarin dosing nomograms. Semin Vasc Med. 2003; 3: 255-260.
30. Levi M, de Peuter OR, Kamphuisen PW. Management strategies for optimal control of anticoagulation in patients with atrial fibrillation. Semin Thromb Hemost. 2009; 35: 560-567.
31. Castellone DD, Van Cott EM. Laboratory monitoring of new anticoagulants. Am J Hematol. 2010; 85: 185-187.
32. van Ryn J, Stangier J, Haertter S, et al. Dabigatran etexilate - a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost 2010; 103: 1116-1127.
33. Douketis JD, Berger PB, Dunn AS, et al. The perioperative management of antithrombotic therapy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition). Chest. 2008; 133 (6 Suppl): 299S-339S.
34. Douketis JD. Pharmacologic properties of the new oral anticoagulants: a clinician-oriented review with a focus on perioperative management. Curr Pharm Des. 2010; 16: 3436-3441.